Hormonal
Once-weekly tirzepatide (5, 10, or 15 mg) combined with lifestyle intervention produces statistically significant and clinically meaningful body weight reductions (up to -22.4%) and improvements in cardiometabolic risk factors in Japanese adults with obesity or overweight.
For Japanese adults with obesity or overweight, adding once-weekly tirzepatide to a standard lifestyle program (calorie deficit and exercise) leads to substantial weight loss (up to ~22%) and improves heart health markers like blood pressure and cholesterol. While injections are required, side effects like nausea are common but usually mild and temporary. This treatment is specifically approved and effective for this demographic, who may face higher health risks at lower BMIs compared to other ethnicities.
Participants in the tirzepatide 5-, 10-, and 15-mg groups had a statistically significantly greater (all p < 0.001) least squares mean (standard error) percent change in body weight compared with those in the placebo group: -12.0% (1.7%), -22.4% (1.7%), -22.1% (1.6%), and -0.3% (1.6%), respectively.
Why this rating
Phase 3 randomized controlled trial data, though limited to a specific subpopulation (Japanese) and smaller sample size (n=102).
Source
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the <scp>SURMOUNT</scp> ‐1 Trial
Yasushi Ishigaki et al. · Obesity · 2026
DOI 10.1002/oby.70131
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →